Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer
Ian D Davis
European Urology | ELSEVIER | Published : 2018
Awarded by Australian NHMRC Practitioner Fellowship
The author is supported by an Australian NHMRC Practitioner Fellowship (APP1102604). He is member and/or chair of various industry advisory boards but receives no remuneration for any of this activity. All payments and honoraria are invoiced by and paid to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. Current advisory boards relevant to this editorial are Astellas, AstraZeneca, and Bayer. Other current advisory boards are Bristol Myers Squibb, Eisai, MSD, Novartis, Pfizer, and Roche. He is unremunerated director and chair of ANZUP. ANZUP is undertaking numerous clinical trials in genitourinary cancers including the ENZAMET trial (ANZUP 1304; NCT02446405) that is directly relevant to the topic of this editorial. The author is global co-chair of the ENZAMET trial with Christopher Sweeney, the senior author of the paper discussed here.